Skip to main content

SPIKEVAX BIVALENT ORIGINAL/OMICRON (elasomeran and imelasomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial, Moderna Australia Pty Ltd, CON-1017

Product name
SPIKEVAX BIVALENT ORIGINAL/OMICRON (elasomeran and imelasomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial
Sponsor name
Moderna Australia Pty Ltd
ARTG
389513
Consent start
Consent no.
CON-1017
Standard
Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines (TGO 91).
Non-compliance with standard
The product is non-compliant with TGO91 in that the labels are international labels.
Conditions imposed
1. The product must be supplied with the labels that were considered and agreed to as  part of the evaluation under section 9D(3) of the Therapeutic Goods Act 1989, being  the 'International Labels', vial and carton labels, for drug product referred to in  submission PM-2022-03959-1-2  as follows: > a) Drug product manufactured at Catalent Indiana LLCi. Vial label for the 0.1 > mg/mL suspension for injection vial: > ii. Carton label for the 0.1 mg/mL suspension for injection vial   > > > > > b) Drug product manufactured at Rovi Pharma Industrial Services, S.A.i. Vial > label for the 0.1 mg/mL suspension for injection vial   ii. Carton label for > the 0.1 mg/mL suspension for injection vial    > c) Drug product manufactured at Samsung Biologics Co. Ltd. i. Vial label for > the 0.1 mg/mL suspension for injection vial   ii. Carton label for the 0.1 > mg/mL suspension for injection vial     
Therapeutic product type
Prescription medicines

Help us improve the Therapeutic Goods Administration site